The pharmacogenetic background of hepatitis C treatment

Schlecker, Christina; Ultsch, Alfred; Geißlinger, Gerd; Lötsch, Jörn

doi:10.1016/j.mrrev.2012.02.001

Cited by 6 publications

(6 citation statements)

References 166 publications

(199 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Differences in the SVR rates were large and clinically meaningful with a ~2‐fold increase in SVR (70–80% vs 40%) observed in patients carrying the favorable IL28B rs12979860 CC genotype. The association of the IL28B genotype with SVR was confirmed by independent studies in various populations from Asia, Europe, and Latin America . The IL28B wild‐type genotype also indicates an increased likelihood of achieving SVR among a pediatric population (rs12979860 CC p=0.01; rs8099917 TT p=0.07; combined p=0.01) …”

Section: Response To Pegifn/rbv Therapy and Il28bmentioning

confidence: 68%

“…However, rs12979860 was considered a better biomarker for African‐Americans due to the stronger association with SVR compared with rs8099917 . Similarly, stronger associations have been reported with rs12979860 than with rs8099917 in studies that investigated both SNPs . The current consensus is that the rs12979860 genotype is the one most likely to predict treatment response if a single SNP has to be selected for diagnostic purposes .…”

Section: Response To Pegifn/rbv Therapy and Il28bmentioning

confidence: 99%

“…The association of the IL28B genotype with SVR was confirmed by independent studies in various populations from Asia, Europe, and Latin America. [21][22][23][24][25][26][27][28][29] The IL28B wild-type genotype also indicates an increased likelihood of achieving SVR among a pediatric population (rs12979860 CC p=0.01; rs8099917 TT p=0.07; combined p=0.01). 30 Although the wild-type IL28B genotype is a strong baseline predictor of SVR, the genotype alone does not completely differentiate responders and nonresponders.…”

Section: Response To Pegifn/rbv Therapy and Il28bmentioning

confidence: 99%

See 2 more Smart Citations

The Role of Pharmacogenetics in the Treatment of Chronic Hepatitis C Infection

Kawaguchi‐Suzuki

Frye

2013

Pharmacotherapy

View full text Add to dashboard Cite

Hepatitis C virus (HCV) chronically infects 170 million people worldwide. Until recently, combination therapy with peginterferon‐α (pegIFN) and ribavirin (RBV) has been the standard of care. However, for many patients, especially those infected with the most common HCV genotype 1 (HCV‐1), this treatment has resulted in unsatisfactory treatment response rates. Many clinical factors, including pharmacogenetics, influence the treatment response rate. Genetic variation in the interleukin 28B (IL28B) gene is the major determinant of treatment response, a finding that has been replicated in multiple independent cohorts. This review focuses on the association between pharmacogenetics and conventional pegIFN/RBV therapy in patients infected with HCV non–genotype 1; patients reinfected with HCV after liver transplantation; and patients coinfected with HCV and human immunodeficiency virus. We also review the pharmacogenetic data for boceprevir and telaprevir triple therapy in patients with HCV‐1 infection, as well as viral genomic polymorphisms and genetic variants that may protect against anemia. Pharmacogenetic information offers a personalized medicine approach to help clinicians and patients make better informed decisions to maximize response and minimize toxicity for the treatment of chronic HCV infection.

show abstract

Section: Response To Pegifn/rbv Therapy and Il28bmentioning

confidence: 68%

Section: Response To Pegifn/rbv Therapy and Il28bmentioning

confidence: 99%

Section: Response To Pegifn/rbv Therapy and Il28bmentioning

confidence: 99%

See 1 more Smart Citation

The Role of Pharmacogenetics in the Treatment of Chronic Hepatitis C Infection

Kawaguchi‐Suzuki

Frye

2013

Pharmacotherapy

View full text Add to dashboard Cite

show abstract

“…Pharmacogenetic testing could play very important role in optimizing HCV therapy by identifying variations in response to treatment, considering ethnic variations in response to therapy, enlightening the molecular mechanism of current and future therapies, and advancement of innovative genetic tools that will enable physicians to individualize drug therapy, adjust dosages, and reduce the possibility of adverse drug reactions and therapeutic costs ( Table 1) [54,58]. Over 40 genes have been linked to modulation of anti-HCV therapy affecting either adverse drug events or response to treatment [59,60]. [7].…”

Section: Hcv Pharmacogenetic Testing In the Ifn Eramentioning

confidence: 99%

Pharmacogenomic Testing in the Era of Patient-Tailored HCV Treatment

Smolić¹,

Omanović²,

Božić³

et al. 2017

Update on Hepatitis C

View full text Add to dashboard Cite

Hepatitis C affects approximately 180 million people worldwide, with 3-4 million newly infected each year. Hepatitis C virus (HCV) has been classified into seven different genotype categories, wherein HCV genotype 1 (HCV-1) is the most prevalent. To date, there is still no vaccine available against HCV infection. Until recently, combination therapy of pegylated interferon-a (PegIFN) and ribavirin (RBV) has been the standard of care. Nevertheless, for many patients, particularly those infected with HCV genotype 1 (HCV-1), this treatment has resulted with unsatisfactory treatment response rates and high adverse drug reaction (ADR) rates. Many clinical factors, including pharmacogenetics, influence the treatment response rate. This review focuses on the association between pharmacogenetics and HCV antiviral therapy in patients infected with HCV genotype 1 and other genotypes (GT); patients reinfected with HCV after liver transplantation; and patients coinfected with HCV and human immunodeficiency virus. Data considering triple therapy in HCV-infected patients are also reviewed. Additionally, various genetic polymorphisms, with an emphasis to IL-28B, and their association with pharmacogenetic testing in HCV are discussed.

show abstract

“…This is due to the fact that those who resolve the infection remain anti-HCV positive for many years [96, 97]. Clearance of hepatitis C depends on many factors such as genetic variants of host's genes [98], virus genotype [99], medical treatment of disease [100, 101], and general status of the immune system. Resolved infections have been frequently associated with a strong HCV-specific cellular immune response [89, 102, 103].…”

Section: Introductionmentioning

confidence: 99%

New Tools in HCV Diagnosis, in Light of the Enhanced Awareness and the New Drugs for Treatment: SMARTube and Stimmunology

Gorodin¹,

Ünal

Wang

et al. 2013

The Scientific World Journal

View full text Add to dashboard Cite

With improved HCV therapy, challenges regarding HCV diagnosis, such as seronegative window period, false positive readings, and differentiation between recent, chronic, and resolved infections, are of increasing importance. To address these challenges an innovative device—SMARTube HIV & HCV—was used. Blood samples were tested for anti-HCV antibodies before and after incubation in the SMARTube, which promotes the in vitro stimulation of in vivo HCV primed lymphocytes, thus enhancing levels of anti-HCV antibodies. Comparing antibody levels, in concordant samples before and after SMARTube, yielded the Stimulation Index (SI). Among 5888 fresh blood samples, from various populations and regions worldwide, 641 were seropositive using plasma, while SMARTube processing (yielding enriched plasma, termed SMARTplasma) enabled diagnosis of 10 additional carriers in high-risk cohorts, that is, earlier detection. Using SMARTplasma eliminated all false positive results, using the current assays. In addition we show that SI calculation may serve as an important tool for differentiating between those who recently seroconverted, carriers of long-term infection, and those who have cleared the virus. SMARTube and the SI could lead to better, more informative diagnosis of HCV infections and play an important role in changing the way we treat both the infected individuals and the epidemic as a whole.

show abstract

The pharmacogenetic background of hepatitis C treatment

Cited by 6 publications

References 166 publications

The Role of Pharmacogenetics in the Treatment of Chronic Hepatitis C Infection

The Role of Pharmacogenetics in the Treatment of Chronic Hepatitis C Infection

Pharmacogenomic Testing in the Era of Patient-Tailored HCV Treatment

New Tools in HCV Diagnosis, in Light of the Enhanced Awareness and the New Drugs for Treatment: SMARTube and Stimmunology

Contact Info

Product

Resources

About